At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Surufatinib +1 moredrug
Likely dose
Surufatinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Open-label, Single-arm, Single-center, Phase II Clinical Study of Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Surufatinib and TAS-102 for Pancreatic Neoplasms. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neoplasms
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartJan 2023
Primary CompletionMar 2025
Study CompletionMay 2025
TodayJul 2026
First PostedAug 1, 2022
Enrollment StartJan 30, 2023
Primary CompletionMar 31, 2025
Study CompletionMay 10, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 3.9 years ago
Interventions
Surufatinibdrug
surufatinib,250mg, qd, po, 28 days for a cycle
TAS-102drug
TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle